Biomarkers and genomics in prostate cancer
|
|
- Laurel Banks
- 6 years ago
- Views:
Transcription
1 Biomarkers and genomics in prostate cancer D. Schrijvers, MD, PhD 1, T. Debacker, MD 2 Biomarkers and genomics are making their entrance in daily clinical practice in many tumour types. In prostate cancer, their use is relatively limited. This article reviews biomarkers and genomics used in different clinical settings such as screening, diagnosis, prognosis, prediction and surrogate endpoints for overall survival and shows an unmet need in prostate cancer. (Belg J Med Oncol 2014;8(4):104-8) Introduction A biomarker is defined as a characteristic that is objectively measured and evaluated as an indicator of normal biological or pathogenic processes, or pharmacologic responses to a therapeutic intervention. 1 Biomarkers are becoming more and more important in cancer because we need factors to identify groups that are in need and benefiting of a certain intervention. In oncology, two important groups of biomarkers are used: Prognostic biomarkers forecast the likely course of disease irrespective of treatment. Predictive biomarkers forecast the likely response to a specific treatment. Biomarkers can be linked to patient- or disease-related factors. Clinical, haematological, biochemical, and genetic factors are being used as biomarkers. Genomics study genes and their functions and related techniques such as determination of different RNA s are becoming part of clinical practice in haematology and oncology. 2 In this review, the status of biomarkers and genomics is discussed in different settings in prostate cancer. Biomarkers and genomics as screening Prostate cancer is a slowly progressing disease and different studies looked at the value of screening to decrease prostate cancer mortality. Several large studies used prostate specific antigen (PSA) in combination with digital rectal examination (DRE) and echography to screen men for prostate cancer. These studies showed that in the screened group, the diagnosis of prostate cancer was higher than in the control group, especially stage II disease. However, there was no improvement in prostate cancer-related mortality after seven and ten years of follow up. 3 Therefore; PSA is not a good biomarker for prostate cancer screening. Also, since there is no survival benefit, prostate cancer screening is not recommended by several scientific organisations. Several high risk groups for prostate cancer development have been defined based on family history. In men with a first-line relative with prostate cancer, the risk of prostate cancer development increases by two-fold, while if there are more than one first-line relative with prostate cancer, the risk increased by five to eleven times. Also, hereditary prostate cancer is present in 5-10% of prostate cancer patients. Genomics may be used to identify men at risk for prostate cancer. In the hereditary breast and ovarian cancer syndrome (BRCA), men carrying a BRCA2 mutation have an increased risk of prostate cancer (odds ratio 4.78; 95% confidence interval ; P = 0.001), while there is no increased risk in BRCA1 mutation carriers. 4 Different genomic wide association studies resulted in the identification of several biological pathways and single 1 Department of Medical Oncology, Ziekenhuisnetwerk Antwerpen-Middelheim, Antwerp, Belgium, 2 Department of Urology, Ziekenhuisnetwerk Antwerpen-Middelheim, Antwerp, Belgium. Please send all correspondence to: D. Schrijvers, MD, PhD, ZNA Middelheim, Department of Medical Oncology, Lindendreef 1, 2020 Antwerp, Belgium, tel: , fax: , Dirk.Schrijvers@zna.be. Conflict of interest: D. Schrijvers - studies with abiraterone acetate and cabazitaxel. Keywords: biomarker, diagnosis, genomics, prediction, prognosis, screening, surrogate endpoint. 104
2 Table 1. Prognostic markers in different situations in prostate cancer. Patient-related Disease-related Others Early stage disease Performance status Co-morbidity Gleason sum in primary tumour T stage PSA Positive tumour margins Perineural invasion Hormone-sensitive metastatic disease Performance status Age Co-morbidity Gleason in primary tumour PSA kinetics Time to reach PSA nadir Castration-resistant metastatic disease Performance status Gleason sum in primary tumour Anaemia Age Visceral disease C-reactive protein Pain Type of progression Lactate dehydrogenase Number sites of disease PSA and PSA by RT-PCR PSA kinetics Albumin Circulating tumour cell count VEGF levels Interleukin-6 levels Chromogranin-A Alkaline phosphatase (bone) Serum TRAP-5b + other bone turnover markers Urine N-telopeptide PSA: prostate specific antigen; RT-PCR: reverse transcription polymerase chain reaction; VEGF: vascular endothelial growth factor; TRAP: tartrate-resistant acid phosphatase. nucleotide polymorphisms associated with an increased risk of prostate cancer. 5,6 At the moment, these techniques are not used in clinical practice and the implication of carrying a mutation in relation to the real risk, as well as primary and secondary prevention and treatment approaches are not well defined. Biomarkers and genomics as diagnostic The diagnosis of prostate cancer is made by a biopsy and this remains the gold standard. However, prostatic biopsies could lead to morbidity and mortality due to complications. The identification of patients who could benefit of a biopsy in daily clinical practice is crucial. Several biomarkers have been studied to limit the number of biopsies in men but all are flawed. Prostate specific antigen is a serum marker that is easily determined. However, at a PSA cut-off point of 4 ng/ml it has a sensitivity of 86% and a specificity of 33%, which means that in patients with a PSA within the normal range, 7-29% have prostate cancer and 1-7% have a prostate cancer with a Gleason score of above seven. 7 The ratio of free to total PSA (f/t PSA) has been used to discriminate between benign prostate hypertrophy and prostate cancer in men with a PSA between 4-10 ng/ml and a negative DRE. The sensitivity in different studies varied between 90-98% but the specificity was low varying from 7-38%. This means that around 10% of prostate cancer can be missed while the number of spared biopsies is between 7 and 38%. 8 PSA kinetics have been studied to improve the diagnostic performance linked to a single PSA determination. PSA velocity determines the absolute annual increase in serum PSA (ng/ml/year), while the PSA doubling time looks at the exponential increase of serum PSA 4 105
3 Table 2. Gene and microrna expression in relation to different prognostic outcomes. Genomic marker Role in prostate cancer Prognostic role Genes CCL-2 Increased cell growth, invasion, metastasis Tumour volume, Gleason score PTEN Decreased invasion, migration Gleason score, stage, BCR, metastasis TMPRSS2-ERG Increased tumour genesis, androgen independence Diagnosis, androgen independence Myc Increased proliferation Progression, survival, BCR after radiation IL-1 Increased tumour genesis Progression IL-6 Increased proliferation Progression TGF-β Increased cell growth, angiogenesis, suppression immune cells Cancer-specific survival IL-7 Immune resistance Cancer-specific survival Micro RNA mir-31 Down regulated invasion Gleason mir-96 Overexpression decrease zinc uptake Gleason mir-145 Upregulated or downregulated Gleason mir-205 Downregulation invasion Gleason, stage mir-32 Overexpression cell survival EPE mir-196a Overexpression cell survival EPE mir-221/222 Overexpression cell survival and proliferation Stage mir-125b Inhibits apoptosis Stage MiR-21 Down regulated invasion and migration BCR mir-135b Overexpression genomic instability BCR mir-194 Overexpression hypomethylation, genomic instability BCR EPE: extracapsular extension; BCR: biochemical recurrence; CCL-2: chemokine (C-C motif) ligand 2; PTEN: phosphatase and tensin homolog; TMPRSS2: transmembrane protease, serine 2; IL: interleukin; TGF: transforming growth factor. over time. Their use in the diagnosis of prostate cancer is limited due to the background noise in relation to the total prostate volume and the presence of benign prostatic hypertrophia, the variations in interval between PSA determinations and the acceleration and deceleration of both over time. 9 The prostate health index (PHI) combines the total PSA, the protein-free PSA and the pro-psa, a subcategory of free PSA. It has a sensitivity of 90% and a specificity of 31.1 %, which makes it a poor diagnostic tool. 10 The prostate cancer gene 3 (PCA3) score is based on the determination of mrna in urine sediment after three strokes of prostatic massage during DRE. At the diagnostic utility score, defined as higher than 35, it has a sensitivity of 61% and a specificity of 70%. This means that at this cut-off, 39% of prostate cancer will be missed, thus making it a poor diagnostic test. 11 In men with a metastatic adenocarcinoma of primary unknown origin, genomic analysis can be used to determine the organ of origin of the disease. Several gene signature profiling tests (e.g. THEROS CancerTYPE ID, Pathwork Tissue of Origin Test, CupPrint, and CUP assay) have been used but their accuracy varies between 76 to 89%, making them less than ideal tests for the diagnosis of prostate cancer. Currently, biopsy remains the golden standard for diagnosing prostate cancer but some tests may indicate men with a higher risk of prostate cancer in need of a biopsy. However, many tests have problems of sensitivity and specificity for detecting prostate cancer accurately. Biomarkers and genomics as prognostic The prognosis of prostate cancer at diagnosis depends on patient-related factors such as life expectancy determined by the calendar and physiologic age, the patient s condi- 106
4 Key messages for clinical practice 1. Biomarkers and genomics are needed but are lacking in prostate cancer. 2. Nomograms can be used for explaining patient prognosis and risk for different endpoints. tion and co-morbidity profile and disease-related factors such as pathological characteristics of the primary tumour (e.g. Gleason score), stage of the disease, and the level of PSA. Based on the disease-related factors, patients are classified in different prognostic groups such as low risk (Gleason score 6, clinical stage T1-2a, PSA < 10 ng/ml), intermediate risk (Gleason score 7, clinical stage T2b, PSA ng/ml) and high risk (Gleason score 8, clinical stage T2c-3a, PSA > 20 ng/ml). 9 In patients with different disease stages (at diagnosis, recurrent disease, castration-resistant disease) several other factors have been defined as prognostic parameters (Table 1). 10,12 Nomograms have been developed in different disease situations and after specific treatments in prostate cancer. They are useful in clinical practice to explain the prognosis to the patient in different situations. Several genomic tests have been developed to predict the prognosis of patients with prostate cancer. Oncotype DX prostate cancer test is an RNA expression test that tests for a 17-gene panel (androgen pathway, cellular organisation, proliferation, stromal response) and is a predictor of high grade and/or pt3 disease. Prolaris is also an RNA expression test based on a 46-gene panel including genes looking at cell cycle progression and cell growth. It is a predictor of 10-year prostate cancer mortality. 13 Although both tests were approved by the Food and Drug Administration (FDA) in the USA, they were not validated in prospective studies and their costs are relatively high (e.g. Prolaris $3,400; Oncotype DX $3,820). Genes and microrna are differently expressed in different situations and gene and/or microrna profiling may be of benefit in determining prognosis for different outcomes (Table 2). 14 They are currently not used in clinical practice. Biomarkers and genomics as predictive Biomarkers and genomics for selecting an adequate treatment are, as yet, not available in clinical practice. In patients with castration-resistant prostate cancer (CRPC), the expression of class III β-tubulin, the silencing of BMI1 gene and the presence of CYP1B1-432ValVal genotype are being studied to see if they can predict response to docetaxel. 15 Biomarkers as surrogate markers for prostate cancer survival Since the median survival of patients with prostate cancer depending on their disease stage is good, overall survival is an endpoint that is not readily reached. Therefore, surrogate endpoints that can predict survival outcome are needed in this patient population to hasten treatment development. The Prentice criteria can be used to determine the value of a surrogate endpoint in relation to the real endpoint. They state that the treatment or intervention must affect the surrogate and true endpoints; that there should be a consistent association between the surrogate and true endpoints with the treatment or intervention; and that there is an association between the surrogate and true endpoints. 16 Circulating tumour cells (CTC) have been tested in different studies in patients with metastatic CRPC to be a surrogate for overall survival. When abiraterone acetate was tested in this setting, it fulfilled all Prentice criteria and the twelve-week CTC number, and the lactate dehydrogenase level biomarker panel demonstrated survival surrogacy at the individual patient level progressing after chemotherapy. 17 However, in a similar patient population, CTC could not predict overall survival in patients treated with the combination of docetaxel and prednisone with or without lenalidomide. 18 Conclusion Biomarkers and genomics presently have limited value in the clinical management of prostate cancer. PSA remains the most widely used biomarker in opportunistic screening while patient- and disease-related factors may be used to determine prognosis. However, there is an unmet need of biomarkers and genomics in prostate cancer to better select patients for specific treatments in different settings
5 References 1. Buyse M, Sargent DJ, Grothey A, et al. Biomarkers and surrogate end pointsthe challenge of statistical validation. Nat Rev Clin Oncol. 2010;7(6): Spans L, Clinckemalie L, Helsen C, et al. The genomic landscape of prostate cancer. Int J Mol Sci. 2013;14(6): Lee YJ, Park JE, Jeon BR, et al. Is prostate-specific antigen effective for population screening of prostate cancer? A systematic review. Ann Lab Med. 2013; 33(4): Kirchhoff T, Kauff ND, Mitra N, et al. BRCA mutations and risk of prostate cancer in Ashkenazi Jews. Clin Cancer Res. 2004;10(9): Hicks C, Miele L, Koganti T, et al. Comprehensive assessment and network analysis of the emerging genetic susceptibility landscape of prostate cancer. Cancer Inform. 2013;12: Ishak MB, Giri VN. A systematic review of replication studies of prostate cancer susceptibility genetic variants in high-risk men originally identified from genome-wide association studies. Cancer Epidemiol Biomarkers Prev. 2011; 20(8): Hoffman RM, Gilliland FD, Adams-Cameron M, et al. Prostate-specific antigen testing accuracy in community practice. BMC Fam Pract. 2002;3: Hara N, Kitamura Y, Saito T, et al. Total and free prostate-specific antigen indexes in prostate cancer screening: value and limitation for Japanese populations. Asian J Androl. 2006;8(4): Heidenreich A, Bastian PJ, Bellmunt J, et al. Guidelines on Prostate Cancer Loeb S, Assimos D, Chancellor MB, et al. Best of the 2013 AUA Annual Meeting: Highlights From the 2013 American Urological Association Meeting, May 4-8, 2013, San Diego, CA. Rev Urol. 2013;15(2): Bradley L, Palomaki G, Gutman S, et al. PCA3 Testing for the Diagnosis and Management of Prostate Cancer. Comparative Effectiveness Review 2013; nr Martin NE, Mucci LA, Loda M, et al. Prognostic Determinants in Prostate Cancer. Cancer J. 2011;17(6): Starr P. Oncotype DX prostate cancer and Prolaris will compete for market share. Value based cancer. (consulted ). 14. Lucas SM, Heath EI. Current challenges in development of differentially expressed and prognostic prostate cancer biomarkers. Prostate Cancer. 2012; 2012: Bitting RL, Armstrong AJ. Potential predictive biomarkers for individualizing treatment for men with castration-resistant prostate cancer. Cancer J. 2013; 19(1): Schold JD, Kaplan B. The elephant in the room: failings of current clinical endpoints in kidney transplantation. Am J Transplant. 2010;10(5): Scher HI, Heller G, Molina A, et al. Evaluation of a composite biomarker panel including circulating tumour cell (CTC) enumeration as a surrogate for survival in metastatic castration-resistant prostate cancer (mcrpc). ECCO 2013; abstr Vogelzang NJ, Petrylak DP Fizazi K, et al. Analysis of circulating tumour cells (CTCs) in a phase 3 study of docetaxel and prednisone (DP) with or without lenalidomide (LEN) in patients (pts) with castrate-resistant prostate cancer (CRPC): The MAINSAIL trial. ECCO 2013; abstr
VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE
Session 3 Advanced prostate cancer VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE 1 PSA is a serine protease and the physiological role is believed to be liquefying the seminal fluid PSA
More informationPSA and the Future. Axel Heidenreich, Department of Urology
PSA and the Future Axel Heidenreich, Department of Urology PSA and Prostate Cancer EAU Guideline 2011 PSA is a continuous variable PSA value (ng/ml) risk of PCa, % 0 0.5 6.6 0.6 1 10.1 1.1 2 17.0 2.1 3
More informationMEDICAL POLICY Genetic and Protein Biomarkers for Diagnosis and Risk Assessment of
POLICY: PG0367 ORIGINAL EFFECTIVE: 08/26/16 LAST REVIEW: 09/27/18 MEDICAL POLICY Genetic and Protein Biomarkers for Diagnosis and Risk Assessment of Prostate Cancer GUIDELINES This policy does not certify
More informationPROSTATE CANCER Importance of Molecular Characteristics in Support of Therapeutic Decisions
PROSTATE CANCER Importance of Molecular Characteristics in Support of Therapeutic Decisions Outline Prognostic and diagnostic value of pathologic and molecular alterations in prostate cancer Current status
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More informationNCCN Guidelines for Prostate V Meeting on 06/28/18
Guideline Page and Request PROS-2 through PROS-11 and PROS-D (pages 3 and 4). External request from GenomeDx Biosciences Request the NCCN Prostate Cancer Guidelines Panel to review the data in support
More informationPersonalized Therapy for Prostate Cancer due to Genetic Testings
Personalized Therapy for Prostate Cancer due to Genetic Testings Stephen J. Freedland, MD Professor of Urology Director, Center for Integrated Research on Cancer and Lifestyle Cedars-Sinai Medical Center
More informationVALUE OF PSA AS TUMOUR MARKER OF RELAPSE AND RESPONSE. ELENA CASTRO Spanish National Cancer Research Centre
VALUE OF PSA AS TUMOUR MARKER OF RELAPSE AND RESPONSE ELENA CASTRO Spanish National Cancer Research Centre Prostate Preceptorship. Lugano 17-18 October 2017 Prostate Specific Antigen (PSA) has a role in:
More informationHow to detect and investigate Prostate Cancer before TRT
How to detect and investigate Prostate Cancer before TRT Frans M.J. Debruyne Professor of Urology Andros Men s Health Institutes, The Netherlands Bruges, 25-26 September 2014 PRISM Recommendations for
More informationCirculating tumor cells as biomarker for hormonal treatment in breast and prostate cancer. Michal Mego
National Cancer Institute, Slovakia Translational Research Unit Circulating tumor cells as biomarker for hormonal treatment in breast and prostate cancer Michal Mego 2 nd Department of Oncology, Faculty
More informationSession 4 Chemotherapy for castration refractory prostate cancer First and second- line chemotherapy
Session 4 Chemotherapy for castration refractory prostate cancer First and second- line chemotherapy October- 2015 ESMO 2004 October- 2015 Fyraftensmøde 2 2010 October- 2015 Fyraftensmøde 3 SWOG 9916 OS
More informationRadical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease
Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease Disclosures I do not have anything to disclose Sexual function causes moderate to severe distress 2 years after
More informationIn autopsy, 70% of men >80yr have occult prostate ca
Prostate Cancer UpToDate: Introduction: Risk Factors: Biology: Symptoms: Diagnosis: Two randomized trials showed survival benefit of adding docetaxol to ADT in fit man with very high localized disease
More informationCytoreductive Radical Prostatectomy for de Novo Metastatic Prostate Cancer
Cytoreductive Radical Prostatectomy for de Novo Metastatic Prostate Cancer Timothy G. Wilson, MD Professor and Chair of Urology John Wayne Cancer Institute Santa Monica, California Disclosures I am on
More informationNew Treatment Modalities and Clinical Trials for HRPC 계명의대 김천일
New Treatment Modalities and Clinical Trials for HRPC 계명의대 김천일 Castrate-Resistant Prostate Cancer (CRPC) Current standard therapy Androgen receptor (AR) in CRPC New systemic therapies Hormonal therapy
More informationClasificación Molecular del Cáncer de Próstata. JM Piulats
Clasificación Molecular del Cáncer de Próstata JM Piulats Introduction The Gleason score is the major method for prostate cancer tissue grading and the most important prognostic factor in this disease.
More informationProstate Cancer in men with germline DNA repair deficiency
Prostate Cancer in men with germline DNA repair deficiency Bruce Montgomery, MD Professor, Medicine and Urology Univ Washington, Fred Hutchinson CRC VA Puget Sound HCS Disclosures Company Tokai, ESSA,
More informationPROSTATE CANCER HORMONE THERAPY AND BEYOND. Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute
PROSTATE CANCER HORMONE THERAPY AND BEYOND Przemyslaw Twardowski MD Professor of Oncology Department of Urologic Oncology John Wayne Cancer Institute Disclosures I am a Consultant for Bayer and Sanofi-Aventis
More informationProstate Cancer Update 2017
Prostate Cancer Update 2017 Arthur L. Burnett, MD, MBA, FACS Patrick C. Walsh Distinguished Professor of Urology The James Buchanan Brady Urological Institute The Johns Hopkins Medical Institutions Baltimore,
More informationJanet E. Dancey NCIC CTG NEW INVESTIGATOR CLINICAL TRIALS COURSE. August 9-12, 2011 Donald Gordon Centre, Queen s University, Kingston, Ontario
Janet E. Dancey NCIC CTG NEW INVESTIGATOR CLINICAL TRIALS COURSE August 9-12, 2011 Donald Gordon Centre, Queen s University, Kingston, Ontario Session: Correlative Studies in Phase III Trials Title: Design
More informationCorporate Medical Policy
Corporate Medical Policy Genetic and Protein Biomarkers for Diagnosis and Risk Assessment of File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_and_protein_biomarkers_for_diagnosis_and_risk_assessment_of_prostate_cancer
More informationPublished on The YODA Project (
Principal Investigator First Name: David Last Name: Lorente Degree: MD Primary Affiliation: Medical Oncology Service, Hospital Provincial de Castellón E-mail: lorente.davest@gmail.com Phone number: +34
More informationProstate Cancer Local or distant recurrence?
Prostate Cancer Local or distant recurrence? Diagnostic flowchart Vanessa Vilas Boas Urologist VFX Hospital FEBU PSA - only recurrence PSA recurrence: 27-53% of all patients undergoing treatment with curative
More informationGenomics and Genetic Testing. Copyright 2017 Myriad Genetics, Inc., all rights reserved.
Genomics and Genetic Testing Copyright 2017 Myriad Genetics, Inc., all rights reserved. www.myriad.com Why is genetic testing important to you? Impact on immediate treatment decisions Identify risks for
More informationWhen exogenous testosterone therapy is. adverse responses can be induced.
Theoretical tips It has been reasoned that discontinuation of ADT in non orchiectomized patients may have detrimental effect on patients with CRPC as discontinuation of ADT can result in renewed release
More informationoriginal research Abstract Introduction
original research A prognostic model for stratifying clinical outcomes in chemotherapy-naive metastatic castration-resistant prostate cancer patients treated with abiraterone acetate Daniel Joseph Khalaf,
More information10/30/2018. Martha K. Terris, MD Witherington Distinguished Professor and Chair Medical College of Georgia Urology November 5, 2018
Martha K. Terris, MD Witherington Distinguished Professor and Chair Medical College of Georgia Urology November 5, 2018 Elevated PSA and/or nodule on digital rectal examination Prostate biopsies If initial
More informationElevated PSA. Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017
Elevated PSA Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017 Issues we will cover today.. The measurement of PSA,
More informationProviding Treatment Information for Prostate Cancer Patients
Providing Treatment Information for Prostate Cancer Patients For all patients with localized disease on biopsy For all patients with adverse pathology after prostatectomy See what better looks like Contact
More informationManagement of castration resistant prostate cancer after first line hormonal therapy fails
Management of castration resistant prostate cancer after first line hormonal therapy fails Simon Crabb Senior Lecturer in Medical Oncology University of Southampton WHAT ARE THE AIMS OF TREATMENT? Cure?
More informationActive surveillance: Shrinking the grey zone. Sommerakademi e Munich, June rd FOIUS Tel Aviv, July 2016
Active surveillance: Shrinking the grey zone Active surveillance: 3 rd FOIUS Tel Aviv, July 2016 Shrinking the grey zone Sommerakademi e Munich, June 30 2016 Active Surveillance for low risk PCa What has
More informationFellow GU Lecture Series, Prostate Cancer. Asit Paul, MD, PhD 02/20/2018
Fellow GU Lecture Series, 2018 Prostate Cancer Asit Paul, MD, PhD 02/20/2018 Disease Burden Screening Risk assessment Treatment Global Burden of Prostate Cancer Prostate cancer ranked 13 th among cancer
More informationWhen exogenous testosterone therapy is. adverse responses can be induced.
Theoretical tips It has been reasoned that discontinuation of ADT in nonorchiectomized patients may have detrimental effect on patients with CRPC as discontinuation of ADT can result in renewed release
More informationSee Submission for References.
Guideline Page and Request PROS-1 External submission from Myriad Genetic Laboratories, Inc. requesting addition of the following statement as a distinct step immediately to the right of life expectancy
More informationProstate Cancer 2009 MDV Anti-Angiogenesis. Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy. Docetaxel/Epothilone
Prostate Cancer 2009 Anti-Angiogenesis MDV 3100 Anti-androgen Radiotherapy Surgery Androgen Deprivation Therapy Docetaxel/Epothilone Abiraterone DC therapy Bisphosphonates Denosumab Secondary Hormonal
More informationControversies in Prostate Cancer Screening
Controversies in Prostate Cancer Screening William J Catalona, MD Northwestern University Chicago Disclosure: Beckman Coulter, a manufacturer of PSA assays, provides research support PSA Screening Recommendations
More informationESMO SUMMIT MIDDLE EAST 2018
ESMO SUMMIT MIDDLE EAST 2018 14 Years of progress in Prostate Cancer Standards of Care and new targets Name Ronald de Wit 6-7 April 2018, Dubai, UAE CONFLICT OF INTEREST DISCLOSURE Sub-title Sanofi Roche
More informationCastrate-resistant prostate cancer: Bone-targeted agents. Pr Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France
Castrate-resistant prostate cancer: Bone-targeted agents Pr Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation in advisory boards or as a speaker for: Amgen, Astellas,
More informationSession VI A: Prostate Cancer Multidisciplinary Approach: a key to success
EORTC-GU Group Session VI A: Prostate Cancer Multidisciplinary Approach: a key to success Joaquim Bellmunt Geriatric Oncology: Cancer in Senior Adults. Madrid Melia Castilla, 8-10 November 2007. Multidisciplinary
More informationStatistical validation of biomarkers and surogate endpoints
Statistical validation of biomarkers and surogate endpoints Marc Buyse, ScD IDDI, Louvain-la-Neuve & Hasselt University, Belgium marc.buyse@iddi.com OUTLINE 1. Setting the scene: definitions and types
More informationMAMTA PARIKH, MD, MS CHALLENGING CASE #2: GU CANCER & STATE OF THE ART: CASTRATION RESISTANT PROSTATE CANCER
MAMTA PARIKH, MD, MS CHALLENGING CASE #2: GU CANCER & STATE OF THE ART: CASTRATION RESISTANT PROSTATE CANCER NO RELEVANT FINANCIAL RELATIONSHIPS IN THE PAST TWELVE MONTHS BY PRESENTER OR SPOUSE/PARTNER.
More informationJoelle Hamilton, M.D.
Joelle Hamilton, M.D. www.urologycentersalabama.com Case Presentation: CRPC, Rising PSA 70 yo healthy, fit, active man post RALP 8 years prior with rising PSA Rising PSA from 0.02 nadir to 3.4 thus ADT
More informationTumor Markers Yesterday, Today & Tomorrow. Steven E. Zimmerman M.D. Vice President & Chief Medical Director
Tumor Markers Yesterday, Today & Tomorrow Steven E. Zimmerman M.D. Vice President & Chief Medical Director Tumor Marker - Definition Substances produced by cancer cells or other cells in response to cancer
More informationMultigene Testing in Prostate Cancer Risk Stratification
Multigene Testing in Prostate Cancer Risk Stratification Ashley Ross, MD, PhD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Objectives Briefly review relevant molecular biology of localized
More informationChallenging Cases. With Q&A Panel
Challenging Cases With Q&A Panel Case Studies Index Patient #1 Jeffrey Wieder, MD Case # 1 72 year old healthy male with mild HTN Early 2011: Preop bone scan and pelvic CT = no mets Radical prostatectomy
More informationDefinition Prostate cancer
Prostate cancer 61 Definition Prostate cancer is a malignant neoplasm that arises from the prostate gland and the most common form of cancer in men. localized prostate cancer is curable by surgery or radiation
More informationFOR PATIENTS DIAGNOSED WITH EARLY-STAGE PROSTATE CANCER. Discover a test that can help you on your treatment journey
FOR PATIENTS DIAGNOSED WITH EARLY-STAGE PROSTATE CANCER Discover a test that can help you on your treatment journey Jim G. Oncotype DX GPS patient navigating prostate cancer since 2014 Not all prostate
More informationwww.drpaulmainwaring.com Figure 1 Androgen action Harris W P et al. (2009) Nat Clin Pract Urol doi:10.1038/ncpuro1296 Figure 2 Mechanisms of castration resistance in prostate cancer Harris W P et al. (2009)
More informationLower Baseline PSA Predicts Greater Benefit From Sipuleucel-T
Lower Baseline PSA Predicts Greater Benefit From Sipuleucel-T Schelhammer PF, Chodak G, Whitmore JB, Sims R, Frohlich MW, Kantoff PW. Lower baseline prostate-specific antigen is associated with a greater
More informationStrategic decisions for systemic treatment. metastatic castration resistant prostate cancer (mcrpc)
Strategic decisions for systemic treatment metastatic castration resistant prostate cancer (mcrpc) SAMO Luzern 14.09.2012 Richard Cathomas Onkologie Kantonsspital Graubünden richard.cathomas@ksgr.ch mcrpc
More informationPrincipal Investigator. General Information. Conflict of Interest Published on The YODA Project (http://yoda.yale.edu)
Principal Investigator First Name: Antonio Last Name: Finelli Degree: MD, MSc, FRCSC Primary Affiliation: Princess Margaret Cancer Centre E-mail: antonio.finelli@uhn.ca Phone number: 416-946-4501 x2851
More informationPSA To screen or not to screen? Darrel Drachenberg, MD, FRCSC
PSA To screen or not to screen? Darrel Drachenberg, MD, FRCSC Disclosures Faculty / Speaker s name: Darrel Drachenberg Relationships with commercial interests: Grants/Research Support: None Speakers Bureau/Honoraria:
More informationPROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS
PROVIDING TREATMENT INFORMATION FOR PROSTATE CANCER PATIENTS For patients with localized disease on biopsy* For patients with adverse pathology after prostatectomy Contact the GenomeDx Customer Support
More informationX, Y and Z of Prostate Cancer
X, Y and Z of Prostate Cancer Dr Tony Michele Medical Oncologist Prostate cancer Epidemiology Current EUA (et al) guidelines on Advanced Prostate Cancer Current clinical management in specific scenarios
More informationSequencing Strategies in Metastatic Castration Resistant Prostate Cancer (MCRPC)
Sequencing Strategies in Metastatic Castration Resistant Prostate Cancer (MCRPC) Amit Bahl Consultant Oncologist Bristol Cancer Institute Clinical Director Spire Specialist Care Centre UK Disclosures Advisory
More informationPROSTATE CANCER SURVEILLANCE
PROSTATE CANCER SURVEILLANCE ESMO Preceptorship on Prostate Cancer Singapore, 15-16 November 2017 Rosa Nadal National Cancer Institute, NIH Bethesda, USA DISCLOSURE No conflicts of interest to declare
More informationPSA is rising: What to do? After curative intended radiotherapy: More local options?
Klinik und Poliklinik für Urologie und Kinderurologie Direktor: Prof. Dr. H. Riedmiller PSA is rising: What to do? After curative intended radiotherapy: More local options? Klinische und molekulare Charakterisierung
More informationProstate Case Scenario 1
Prostate Case Scenario 1 H&P 5/12/16: A 57-year-old Hispanic male presents with frequency of micturition, urinary urgency, and hesitancy associated with a weak stream. Over the past several weeks, he has
More informationCase Discussions: Prostate Cancer
Case Discussions: Prostate Cancer Andrew J. Stephenson, MD FRCSC FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Elevated PSA 1 54 yo, healthy male, family Hx of
More informationFocus on... Prostate Health Index (PHI) Proven To Outperform Traditional PSA Screening In Predicting Clinically Significant Prostate Cancer
Focus on... Prostate Health Index (PHI) Proven To Outperform Traditional PSA Screening In Predicting Clinically Significant Prostate Cancer Prostate Cancer in Ireland & Worldwide In Ireland, prostate cancer
More informationRationale Design of Combination Therapy in Prostate Cancer: Targeting the AR and PI3K pathways
Rationale Design of Combination Therapy in Prostate Cancer: Targeting the AR and PI3K pathways Brett S Carver, MD Assistant Attending, Department of Surgery/Urology Prostate Cancer Therapeutics: A Changed
More informationNewer Aspects of Prostate Cancer Underwriting
Newer Aspects of Prostate Cancer Underwriting Presented By: Jack Swanson, M.D. Keith Hoffman, NFP Moments Made Possible Objectives To review and discuss Conflicting messages about PSA testing Cautions
More informationGene expression profiling predicts clinical outcome of prostate cancer. Gennadi V. Glinsky, Anna B. Glinskii, Andrew J. Stephenson, Robert M.
SUPPLEMENTARY DATA Gene expression profiling predicts clinical outcome of prostate cancer Gennadi V. Glinsky, Anna B. Glinskii, Andrew J. Stephenson, Robert M. Hoffman, William L. Gerald Table of Contents
More informationProstate CancerTest TM. Test Report
Test Report Patient Information Requisition Number Patient Name ID Number Date of Birth Gender M Patient Phone Number Patient E-mail Name of Lab Lab Phone Number Name of Physician Date of Collection Date
More informationCorrespondence should be addressed to Taha Numan Yıkılmaz;
Advances in Medicine Volume 2016, Article ID 8639041, 5 pages http://dx.doi.org/10.1155/2016/8639041 Research Article External Validation of the Cancer of the Prostate Risk Assessment Postsurgical Score
More informationManagement of Prostate Cancer
Management of Prostate Cancer An ESMO Perspective Alan Horwich Conflicts of Interest Disclosure Alan Horwich I have no personal conflicts of interest relating to prostate cancer. European Incidence and
More informationAdditional Disclosure
Additional Disclosure The Genetics of Prostate Cancer: Clinical Implications William J. Catalona, MD Collaborator with decode genetics, Inc. Non-paid consultant with no financial interest or support Northwestern
More informationPreoperative Gleason score, percent of positive prostate biopsies and PSA in predicting biochemical recurrence after radical prostatectomy
JBUON 2013; 18(4): 954-960 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE Gleason score, percent of positive prostate and PSA in predicting biochemical
More informationCurrent role of chemotherapy in hormone-naïve patients Elena Castro
Current role of chemotherapy in hormone-naïve patients Elena Castro Spanish National Cancer Research Centre Lugano, 17 October 2017 Siegel, Ca Cancer J Clin,2017 Buzzoni, Eur Urol, 2015 -Aprox 15-20% of
More informationMicroRNA expression profiling and functional analysis in prostate cancer. Marco Folini s.c. Ricerca Traslazionale DOSL
MicroRNA expression profiling and functional analysis in prostate cancer Marco Folini s.c. Ricerca Traslazionale DOSL What are micrornas? For almost three decades, the alteration of protein-coding genes
More informationPCa Commentary. Volume 83 September October 2013
1221 Madison Street, First Floor Seattle, WA 98104 P 206-215-2480 ww.seattleprostate.com PCa Commentary Volume 83 September October 2013 Table of Contents Alpharadin, Xofigo Page 1 PTEN gene Page 3 ALPHARADIN
More informationOutcomes of Radical Prostatectomy in Thai Men with Prostate Cancer
Original Article Outcomes of Radical Prostatectomy in Thai Men with Prostate Cancer Sunai Leewansangtong, Suchai Soontrapa, Chaiyong Nualyong, Sittiporn Srinualnad, Tawatchai Taweemonkongsap and Teerapon
More informationSIMPOSIO. Radioterapia stereotassica e nuovi farmaci nel tumore e della prostata metastatico
SIMPOSIO Radioterapia stereotassica e nuovi farmaci nel tumore e della prostata metastatico Definition of Oligometastatic PCa 1-3 synchronous metastases (bone and/or lymph nodes) 2-5 synchronous metastases
More informationManagement of castrate resistant disease: after first line hormone therapy fails
Management of castrate resistant disease: after first line hormone therapy fails Rob Jones Consultant in Medical Oncology Beatson Cancer Centre Glasgow Relevant Disclosure I have received research support
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Abiraterone for the treatment of metastatic castration-resistant prostate cancer that has progressed on or after a docetaxel-based chemotherapy regimen Disease
More informationGUIDELINES ON PROSTATE CANCER
10 G. Aus (chairman), C. Abbou, M. Bolla, A. Heidenreich, H-P. Schmid, H. van Poppel, J. Wolff, F. Zattoni Eur Urol 2001;40:97-101 Introduction Cancer of the prostate is now recognized as one of the principal
More informationUpdates in Prostate Cancer Treatment 2018
Updates in Prostate Cancer Treatment 2018 Mountain States Cancer Conference Elaine T. Lam, MD November 3, 2018 Learning Objectives Understand the difference between hormone sensitive and castration resistant
More informationTowards Early and More Specific Diagnosis of Prostate Cancer? Beyond PSA: New Biomarkers Ready for Prime Time
european urology supplements 8 (2009) 97 102 available at www.sciencedirect.com journal homepage: www.europeanurology.com Towards Early and More Specific Diagnosis of Prostate Cancer? Beyond PSA: New Biomarkers
More informationSummary... 2 GENITOURINARY TUMOURS - PROSTATE... 3
ESMO 2016 Congress 7-11 October, 2016 Copenhagen, Denmark Table of Contents Summary... 2 GENITOURINARY TUMOURS - PROSTATE... 3 Custirsen provides no additional survival benefit to cabazitaxel/prednisone
More information3/6/2018 PROSTATE CANCER IN 2018 OBJECTIVE WHAT IS THE PROSTATE? WHAT DOES IT DO? Rahul Mehan, MD
PROSTATE CANCER IN 2018 Rahul Mehan, MD East Valley Urology Center 6116 E Arbor Ave, Bldg 2, Suite 108 Mesa, AZ 85206 rmehan@evucenter.com www.evucenter.com Snapchat: Dr.NoodleKing OBJECTIVE Offer interactive
More informationconcordance indices were calculated for the entire model and subsequently for each risk group.
; 2010 Urological Oncology ACCURACY OF KATTAN NOMOGRAM KORETS ET AL. BJUI Accuracy of the Kattan nomogram across prostate cancer risk-groups Ruslan Korets, Piruz Motamedinia, Olga Yeshchina, Manisha Desai
More informationHow will new biomarkers change prostate cancer management
How will new biomarkers change prostate cancer management Matthew R. Cooperberg, MD, MPH Departments of Urology and Epidemiology & Biostatistics BAUS Section of Oncology Annual Meeting Cardiff, UK 15 November
More informationEvaluation of prognostic factors after radical prostatectomy in pt3b prostate cancer patients in Japanese population
Japanese Journal of Clinical Oncology, 2015, 45(8) 780 784 doi: 10.1093/jjco/hyv077 Advance Access Publication Date: 15 May 2015 Original Article Original Article Evaluation of prognostic factors after
More informationACTIVE SURVEILLANCE OR WATCHFUL WAITING
Prostate Cancer ACTIVE SURVEILLANCE OR WATCHFUL WAITING María Teresa Bourlon, MD MS Head, Urologic Oncology Clinic Hemato-Oncology Department Instituto Nacional de Ciencias Médicas y Nutrición Salvador
More informationHealth Screening Update: Prostate Cancer Zamip Patel, MD FSACOFP Convention August 1 st, 2015
Health Screening Update: Prostate Cancer Zamip Patel, MD FSACOFP Convention August 1 st, 2015 Outline Epidemiology of prostate cancer Purpose of screening Method of screening Contemporary screening trials
More informationSecondary Hormonal therapies in mcrpc
Secondary Hormonal therapies in mcrpc Ravindran Kanesvaran Consultant,Division of Medical Oncology National Cancer Centre Singapore 1 Disclosures Research Support/P.I. Sanofi Consultant Major Stockholder
More informationState-of-the-art: vision on the future. Urology
State-of-the-art: vision on the future Urology Francesco Montorsi MD FRCS Professor and Chairman Department of Urology San Raffaele Hospital Vita-Salute San Raffaele University Milan, Italy Disclosures
More informationThe Prognostic Importance of Prostate-Specific Antigen in Monitoring Patients Undergoing Maximum Androgen Blockage for Metastatic Prostate Cancer
Research Article TheScientificWorldJOURNAL (005) 5, 8 4 ISSN 57-744X; DOI 0.00/tsw.005.9 The Prognostic Importance of Prostate-Specific Antigen in Monitoring Patients Undergoing Maximum Androgen Blockage
More informationSupplementary Material
Supplementary Material Identification of mir-187 and mir-182 as biomarkers for early diagnosis and prognosis in prostate cancer patients treated with radical prostatectomy Irene Casanova-Salas 1, José
More informationDetection & Risk Stratification for Early Stage Prostate Cancer
Detection & Risk Stratification for Early Stage Prostate Cancer Andrew J. Stephenson, MD, FRCSC, FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Risk Stratification:
More informationNIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More informationOutline. Outline. Phillip G. Febbo, MD. Genomic Approaches to Outcome Prediction in Prostate Cancer
Genomic Approaches to Outcome Prediction in Prostate Cancer Phillip G. Febbo, MD Duke Institute for Genome Science and Policy Department of Medicine Department of Molecular Genetics and Microbiology Duke
More informationWhen PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy
When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA
More informationPerspective on endocrine and chemotherapy agents. Cora N. Sternberg Department of Medical Oncology San Camillo & Forlanini Hospitals Rome, Italy
Perspective on endocrine and chemotherapy agents Cora N. Sternberg Department of Medical Oncology San Camillo & Forlanini Hospitals Rome, Italy Disclosures Dr. Sternberg has received research funding for
More informationScreening and Risk Stratification of Men for Prostate Cancer Metastasis and Mortality
Screening and Risk Stratification of Men for Prostate Cancer Metastasis and Mortality Sanoj Punnen, MD, MAS Assistant Professor of Urologic Oncology University of Miami, Miller School of Medicine and Sylvester
More informationProstate Cancer. Dr. Andres Wiernik 2017
Prostate Cancer Dr. Andres Wiernik 2017 Objectives YES!!! 1. Epidemiology 2. Biology or Natural History of Prostate Cancer 3. Treatment NO!!! 1. Prostate Cancer Screening - controversies Which is the most
More informationBiomarkers in Prostate Cancer
Biomarkers in Prostate Cancer Current clinical implications and future perspectives Rui Henrique Serviço de Anatomia Patológica e Centro de Investigação Instituto Português de Oncologia do Porto Francisco
More informationBone-targeted therapies for prostate cancer in Institut Gustave Roussy Villejuif, France
Bone-targeted therapies for prostate cancer in 2012 Pr Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation to advisory boards or speaker for: Amgen, Astellas-Medivation,
More informationNCCN Guidelines for Prostate Cancer V Web teleconference 06/17/16 and 06/30/17
Guideline Page and Request PROS-1 Submission from Myriad Genetic Laboratories, Inc. Request addition of recommendation for genetic risk assessment/testing to the Initial Clinical Assessment algorithm for
More informationAdam Raben M.D. Helen F Graham Cancer Center
Adam Raben M.D. Helen F Graham Cancer Center Is the biopsy sample representative of the extent of the disease in your patient with clinically low-risk prostate cancer? BIOPSY RP registry (n=8095) 3+3=6
More information